CN112153984A - 化合物及其用途 - Google Patents

化合物及其用途 Download PDF

Info

Publication number
CN112153984A
CN112153984A CN201980023925.9A CN201980023925A CN112153984A CN 112153984 A CN112153984 A CN 112153984A CN 201980023925 A CN201980023925 A CN 201980023925A CN 112153984 A CN112153984 A CN 112153984A
Authority
CN
China
Prior art keywords
optionally substituted
compound
cancer
μmol
alkyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201980023925.9A
Other languages
English (en)
Chinese (zh)
Inventor
N·J·安东尼
D·S·米兰
R·G·瓦斯瓦尼
S·E·R·席勒
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Fuhong Treatment Co
Original Assignee
Fuhong Treatment Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Fuhong Treatment Co filed Critical Fuhong Treatment Co
Publication of CN112153984A publication Critical patent/CN112153984A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D277/38—Nitrogen atoms
    • C07D277/44—Acylated amino or imino radicals
    • C07D277/46—Acylated amino or imino radicals by carboxylic acids, or sulfur or nitrogen analogues thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/541—Non-condensed thiazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4409—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 4, e.g. isoniazid, iproniazid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4425—Pyridinium derivatives, e.g. pralidoxime, pyridostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B18/00—Surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body
    • A61B2018/00571—Surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body for achieving a particular surgical effect
    • A61B2018/00589—Coagulation

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
CN201980023925.9A 2018-01-30 2019-01-29 化合物及其用途 Pending CN112153984A (zh)

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
US201862623907P 2018-01-30 2018-01-30
US62/623907 2018-01-30
US201862653229P 2018-04-05 2018-04-05
US62/653229 2018-04-05
US201862770431P 2018-11-21 2018-11-21
US62/770431 2018-11-21
US201962789260P 2019-01-07 2019-01-07
US62/789260 2019-01-07
PCT/US2019/015722 WO2019152437A1 (en) 2018-01-30 2019-01-29 Compounds and uses thereof

Publications (1)

Publication Number Publication Date
CN112153984A true CN112153984A (zh) 2020-12-29

Family

ID=67478426

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201980023925.9A Pending CN112153984A (zh) 2018-01-30 2019-01-29 化合物及其用途

Country Status (5)

Country Link
US (2) US11497752B2 (enExample)
EP (1) EP3746124A4 (enExample)
JP (1) JP2021512166A (enExample)
CN (1) CN112153984A (enExample)
WO (1) WO2019152437A1 (enExample)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017087885A1 (en) 2015-11-19 2017-05-26 Dana-Farber Cancer Institute, Inc. Methods of identifying compounds that interfere with erg-driven misguidance of baf complexes in tmprss2-erg driven prostate cancers
WO2019140380A1 (en) 2018-01-12 2019-07-18 Kymera Therapeutics, Inc. Protein degraders and uses thereof
US11497752B2 (en) 2018-01-30 2022-11-15 Foghorn Therapeutics Inc. Compounds and uses thereof
WO2020010227A1 (en) 2018-07-06 2020-01-09 Kymera Therapeutics, Inc. Protein degraders and uses thereof
WO2020081588A1 (en) 2018-10-17 2020-04-23 Dana-Farber Cancer Institute, Inc. Swi/snf family chromatin remodeling complexes and uses thereof
SG11202106444WA (en) 2018-12-19 2021-07-29 Leo Pharma As Amino-acid anilides as small molecule modulators of il-17
CN113645971B (zh) * 2019-01-29 2024-10-18 福宏治疗公司 化合物及其用途
EP3917517A4 (en) 2019-01-29 2023-01-25 Foghorn Therapeutics Inc. CONNECTIONS AND USES THEREOF
CN113874016A (zh) 2019-01-29 2021-12-31 福宏治疗公司 化合物及其用途
US12384776B2 (en) 2019-01-29 2025-08-12 Foghorn Therapeutics Inc. Compounds and uses thereof
US12509453B2 (en) 2019-01-29 2025-12-30 Foghorn Therapeutics Inc. BRM/BRG1 inhibitors and uses thereof
WO2020251972A1 (en) 2019-06-10 2020-12-17 Kymera Therapeutics, Inc. Smarca degraders and uses thereof
WO2021022163A2 (en) 2019-07-31 2021-02-04 Foghorn Therapeutics Inc. Compounds and uses thereof
US11845724B2 (en) 2019-09-11 2023-12-19 Vincere Biosciences, Inc. USP30 inhibitors and uses thereof
WO2021133917A1 (en) 2019-12-23 2021-07-01 Kymera Therapeutics, Inc. Smarca inhibitors and uses thereof
EP4081308A4 (en) 2019-12-23 2024-01-24 Kymera Therapeutics, Inc. Smarca degraders and uses thereof
AU2021213811A1 (en) * 2020-01-29 2022-07-28 Foghorn Therapeutics Inc. Compounds and uses thereof
US12528825B2 (en) 2020-01-29 2026-01-20 Foghorn Therapeutics Inc. Compounds and uses thereof
CN115484948A (zh) 2020-01-29 2022-12-16 福宏治疗公司 化合物及其用途
EP4096667A4 (en) * 2020-01-29 2024-03-06 Foghorn Therapeutics Inc. COMPOUNDS AND USES THEREOF
WO2021155264A1 (en) 2020-01-29 2021-08-05 Foghorn Therapeutics Inc. Compounds and uses thereof
EP4096651A4 (en) 2020-01-29 2024-01-24 Foghorn Therapeutics Inc. COMPOUNDS AND THEIR USES
JP7693688B2 (ja) * 2020-01-29 2025-06-17 フォグホーン セラピューティクス インコーポレイテッド 化合物およびその使用
US12383555B2 (en) 2020-05-20 2025-08-12 Foghorn Therapeutics Inc. Methods of treating cancers
EP4153176A4 (en) * 2020-05-20 2024-05-29 Foghorn Therapeutics Inc. METHODS OF TREATING CANCER
US11787800B2 (en) 2020-07-29 2023-10-17 Foghorn Therapeutics Inc. BRD9 degraders and uses thereof
AU2021359129A1 (en) * 2020-10-16 2023-06-01 Proxygen Gmbh Heterocyclic cullin ring ubiquitin ligase compounds and uses thereof
CA3198317A1 (en) * 2020-11-10 2022-05-19 Kevin J. Wilson Compounds and uses thereof
EP4259144A4 (en) 2020-12-09 2025-08-20 Kymera Therapeutics Inc SMARCA DEGRADING AGENTS AND THEIR USES
EP4294790A4 (en) * 2021-02-19 2025-02-26 Kymera Therapeutics, Inc. SMARCA DEGRADING AGENTS AND RELATED USES
US12606553B2 (en) 2021-03-09 2026-04-21 Foghorn Therapeutics Inc. Crystalline forms, compositions containing same, and methods of their use
US11767330B2 (en) 2021-07-06 2023-09-26 Foghorn Therapeutics Inc. Citrate salt, pharmaceutical compositions, and methods of making and using the same
US20240374605A1 (en) * 2021-07-29 2024-11-14 Foghorn Therapeutics Inc. Methods of treating cancer
WO2024086577A1 (en) * 2022-10-17 2024-04-25 Foghorn Therapeutics Inc. Methods of reducing or preventing metastases
WO2024099440A1 (zh) * 2022-11-11 2024-05-16 苏州信诺维医药科技股份有限公司 一种稠环化合物、其用途及含其的药物组合物
WO2025017207A1 (en) * 2023-07-20 2025-01-23 Cemm - Forschungszentrum Für Molekulare Medizin Gmbh Inhibitors of smndc1 and their therapeutic use

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3717642A (en) * 1969-07-22 1973-02-20 Warner Lambert Co N quinoline 5 aminooxazoles
CN103038231A (zh) * 2010-03-17 2013-04-10 台维克斯医疗公司 Hec1活性调节剂及其方法
WO2015120320A1 (en) * 2014-02-06 2015-08-13 Rutgers, The State University Of New Jersey Antibacterial agents: n(alpha)-aroyl-n-aryl-phenylalaninamides
CN105473141A (zh) * 2013-03-15 2016-04-06 实发生物医学公司 治疗和/或预防心血管疾病的抗pcsk9化合物和方法
CN107531668A (zh) * 2015-02-25 2018-01-02 基因泰克公司 治疗性哒嗪化合物及其用途

Family Cites Families (156)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2788341A (en) * 1953-03-06 1957-04-09 Ciba Pharm Prod Inc Process for the manufacture of aminoacyl compounds
US4109496A (en) 1977-12-20 1978-08-29 Norris Industries Trapped key mechanism
US4147343A (en) 1978-02-25 1979-04-03 Hyde Phillip R Acrobatic amusement device
FR2568880B1 (fr) 1984-08-07 1986-12-12 Synthelabo Derives d'acylaminomethyl-3 imidazo(1,2-a)pyridines, leur preparation et leur application en therapeutique
US4868103A (en) 1986-02-19 1989-09-19 Enzo Biochem, Inc. Analyte detection by means of energy transfer
US5080891A (en) 1987-08-03 1992-01-14 Ddi Pharmaceuticals, Inc. Conjugates of superoxide dismutase coupled to high molecular weight polyalkylene glycols
DE68905707T2 (de) 1988-08-10 1993-08-19 Tokyo Sintered Metals Corp Fahrradaehnliches trainingsgeraet.
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
US6534055B1 (en) 1988-11-23 2003-03-18 Genetics Institute, Inc. Methods for selectively stimulating proliferation of T cells
US6905680B2 (en) 1988-11-23 2005-06-14 Genetics Institute, Inc. Methods of treating HIV infected subjects
US5858358A (en) 1992-04-07 1999-01-12 The United States Of America As Represented By The Secretary Of The Navy Methods for selectively stimulating proliferation of T cells
US6352694B1 (en) 1994-06-03 2002-03-05 Genetics Institute, Inc. Methods for inducing a population of T cells to proliferate using agents which recognize TCR/CD3 and ligands which stimulate an accessory molecule on the surface of the T cells
US5016870A (en) 1990-02-09 1991-05-21 Bulloch Russell G Exercise device
AU643140B2 (en) 1991-05-31 1993-11-04 Sumitomo Pharmaceuticals Company, Limited Leukotriene B4 antagonist
EP0552108B1 (en) 1992-01-17 1999-11-10 Lakowicz, Joseph R. Energy transfer phase-modulation fluoro-immunoassay
WO1994010300A1 (en) 1992-10-30 1994-05-11 The General Hospital Corporation Interaction trap system for isolating novel proteins
US5569128A (en) 1994-02-03 1996-10-29 Icon Health & Fitness, Inc. Leg and upper body exerciser
US5656465A (en) 1994-05-04 1997-08-12 Therion Biologics Corporation Methods of in vivo gene delivery
US7175843B2 (en) 1994-06-03 2007-02-13 Genetics Institute, Llc Methods for selectively stimulating proliferation of T cells
US7067318B2 (en) 1995-06-07 2006-06-27 The Regents Of The University Of Michigan Methods for transfecting T cells
US6692964B1 (en) 1995-05-04 2004-02-17 The United States Of America As Represented By The Secretary Of The Navy Methods for transfecting T cells
US5677158A (en) 1995-06-07 1997-10-14 Research Foundation Of State University Of New York In vitro packaging of adeno-associated virus DNA
US5801030A (en) 1995-09-01 1998-09-01 Genvec, Inc. Methods and vectors for site-specific recombination
US6180612B1 (en) 1997-10-31 2001-01-30 The University Of Virginia Patent Foundation Methods and compositions for targeting DNA metabolic processes using aminoglycoside derivatives
US6683058B1 (en) 1998-04-15 2004-01-27 Regents Of The University Of California Methods for therapy of neurodegenerative disease of the brain
WO1999061066A2 (en) 1998-05-27 1999-12-02 Avigen, Inc. Convection-enhanced delivery of aav vectors
JP2000095767A (ja) 1998-09-28 2000-04-04 Takeda Chem Ind Ltd 性腺刺激ホルモン放出ホルモン拮抗剤
WO2000024392A1 (en) * 1998-10-26 2000-05-04 Sumitomo Pharmaceuticals Company, Limited β-AMYLOID FORMATION INHIBITORS
CA2369553A1 (en) 1999-04-02 2000-10-12 Raymond F. Horvath N-benzimidazolylmethyl and n-indolylmethyl-benzamides and their use as crf modulators
WO2000059905A1 (en) 1999-04-02 2000-10-12 Neurogen Corporation ARYL AND HETEROARYL FUSED AMINOALKYL-IMIDAZOLE DERIVATIVES: SELECTIVE MODULATORS OF GABAa RECEPTORS
WO2001059094A2 (en) 2000-02-11 2001-08-16 The Salk Institute For Biological Studies Method of regulating transcription in a cell by altering remodeling of cromatin
US6867041B2 (en) 2000-02-24 2005-03-15 Xcyte Therapies, Inc. Simultaneous stimulation and concentration of cells
US7572631B2 (en) 2000-02-24 2009-08-11 Invitrogen Corporation Activation and expansion of T cells
US6797514B2 (en) 2000-02-24 2004-09-28 Xcyte Therapies, Inc. Simultaneous stimulation and concentration of cells
KR20030032922A (ko) 2000-02-24 2003-04-26 싸이트 테라피스 인코포레이티드 세포의 동시 자극 및 농축
US6547702B1 (en) 2000-03-29 2003-04-15 Innovative Applications, Inc. Exercise device
US20020037281A1 (en) 2000-05-26 2002-03-28 Davidson Beverly L. Methods of transducing neural cells using lentivirus vectors
US20030027335A1 (en) 2000-09-07 2003-02-06 Ruley H. Earl Genome engineering by cell-permeable DNA site-specific recombinases
US6562576B2 (en) 2001-01-04 2003-05-13 Myriad Genetics, Inc. Yeast two-hybrid system and use thereof
JP2003033179A (ja) 2001-07-05 2003-02-04 Asahi Kasei Corp 可逆的遺伝子導入ベクター
JP2003077651A (ja) 2001-08-30 2003-03-14 Sharp Corp 有機エレクトロルミネッセンス素子の製造方法
US7132438B2 (en) 2001-10-09 2006-11-07 Amgen Inc. Benzimidazole derivatives
US20050079512A1 (en) 2003-02-26 2005-04-14 Emerson Beverly M. Methods of modulating gene expression
US20040216178A1 (en) 2003-03-03 2004-10-28 Jones Stephen N Regulation of mdm2 function
WO2005007877A2 (en) 2003-07-18 2005-01-27 University Of Massachusetts Regulatable promoters for synthesis of small hairpin rna
BRPI0415563A (pt) 2003-10-20 2007-01-02 Nsgene As método para o tratamento do mal de parkinson, uso de um vetor viral, vetor de expressão viral, composição farmacêutica, célula hospedeira isolada, linhagem de células de empacotamento, mamìfero não humano quimérico, dispositivo de cultura celular implantável, cápsula biocompatìvel, método para tratamento de uma doença do sistema nervoso, célula de mamìfero, e, método para produzir neurturin ou um seu equivalente funcional
US20060058255A1 (en) 2004-03-01 2006-03-16 Jianzhu Chen RNAi-based therapeutics for allergic rhinitis and asthma
WO2005112620A2 (en) 2004-05-18 2005-12-01 Massachusetts Institute Of Technology A cre-lox based method for conditional rna interference
AU2005261487A1 (en) * 2004-07-12 2006-01-19 Istituto Di Ricerche Di Biologia Molecolare P. Angeletti S.P.A. Amide derivatives as inhibitors of histone deacetylase
RU2007121864A (ru) 2004-11-11 2008-12-20 Феррер Интернасионал ИМИДАЗО[1,2-a]ПИРИДИНОВЫЕ СОЕДИНЕНИЯ (ВАРИАНТЫ), СПОСОБ ИХ ПОЛУЧЕНИЯ (ВАРИАНТЫ), КОМПОЗИЦИЯ НА ИХ ОСНОВЕ, СПОСОБ ЛЕЧЕНИЯ ИЛИ ПРОФИЛАКТИКИ ЗАБОЛЕВАНИЙ, СВЯЗАННЫХ С МОДУЛЯЦИЕЙ РЕЦЕПТОРОВ GABAA, ИЛИ α1-GABAA, ИЛИ α2-GABAA (ВАРИАНТЫ)
WO2006070806A1 (ja) 2004-12-28 2006-07-06 Taiho Pharmaceutical Co., Ltd. 新規ベンゾイミダゾール化合物及び該化合物を含有する医薬組成物
WO2006119435A2 (en) 2005-05-04 2006-11-09 Invitrogen Corporation Identification of cancer biomarkers and phosphorylated proteins
AU2007288124B2 (en) 2006-08-24 2013-04-04 Australian Nuclear Science & Technology Organisation Fluorinated ligands for targeting peripheral benzodiazepine receptors
US8324367B2 (en) 2006-11-03 2012-12-04 Medtronic, Inc. Compositions and methods for making therapies delivered by viral vectors reversible for safety and allele-specificity
CA2688194A1 (en) 2007-05-23 2008-12-04 Siga Technologies, Inc. Antiviral drugs for treatment or prevention of dengue infection
WO2008157500A1 (en) 2007-06-17 2008-12-24 Kalypsys, Inc. Aminoquinazoline cannabinoid receptor modulators for treatment of disease
US7927258B2 (en) 2007-08-17 2011-04-19 Real Ryder, LLC Bicycling exercise apparatus
WO2009086303A2 (en) 2007-12-21 2009-07-09 University Of Rochester Method for altering the lifespan of eukaryotic organisms
CA2618163A1 (en) 2008-02-07 2009-08-07 K. W. Michael Siu Head and neck cancer biomarkers
CA2716947A1 (en) 2008-02-29 2009-09-11 Array Biopharma Inc. Imidazo [4,5-b] pyridine derivatives used as raf inhibitors
EP2349484A2 (en) * 2008-07-15 2011-08-03 Novartis AG Heteroaryl derivatives as dgat1 inhibitors
KR20110128283A (ko) 2009-02-05 2011-11-29 타겟티드 딜리버리 테크놀러지스 리미티드 미생물체의 증식 및 생존도를 감소시키는 방법
BR112012027104B8 (pt) 2010-04-22 2020-02-27 British Columbia Cancer Agency Branch método de acordo para determinar se a endometriose de um individuo é suscetível de progredir para carcinoma de células claras ovariano , carcinoma endometrioide, carcinoma endometrial e carcinoma uterino, para determinar a prognose para uma pessoa sofrendo de carcinoma de células claras ovariano, e/ou para determinar se agentes quimioterapêuticos padrões são prováveis de serem efetivos no tratamento de carcinoma de células claras ovariano, carcinoma endometrioide, carcinoma endometrial e carcinoma uterino
US20120035244A1 (en) 2010-07-29 2012-02-09 The Regents Of The University Of Michigan Parp1 targeted therapy
US9072052B2 (en) 2010-08-09 2015-06-30 Blackberry Limited Communication system providing context-based mobile wireless communications device power consumption management and related methods
US8647240B2 (en) 2010-10-08 2014-02-11 Innovative Applications, Inc. Exercise device
EP2655330B1 (en) 2010-12-22 2016-02-10 Purdue Pharma LP Substituted pyridines as sodium channel blockers
EP2694678A2 (en) 2011-04-04 2014-02-12 Netherland Cancer Institute Methods and compositions for predicting resistance to anticancer treatment
ES2733211T3 (es) 2011-04-15 2019-11-28 Genelux Corp Cepas clonales de virus vaccinia atenuados y métodos de uso de las mismas
JP6175078B2 (ja) 2012-02-01 2017-08-02 ザ トラスティーズ オブ コロンビア ユニヴァーシティ イン ザ シティ オブ ニューヨーク 新規のシステインプロテアーゼ阻害剤及びその使用
EP2809660B1 (en) 2012-02-02 2016-01-20 Ensemble Therapeutics Corporation Macrocyclic compounds for modulating il-17
US9227106B2 (en) 2012-05-21 2016-01-05 Todd Richards Weight lifting machine
AU2013266968B2 (en) 2012-05-25 2017-06-29 Emmanuelle CHARPENTIER Methods and compositions for RNA-directed target DNA modification and for RNA-directed modulation of transcription
US8697359B1 (en) 2012-12-12 2014-04-15 The Broad Institute, Inc. CRISPR-Cas systems and methods for altering expression of gene products
EP2840140B2 (en) 2012-12-12 2023-02-22 The Broad Institute, Inc. Crispr-Cas based method for mutation of prokaryotic cells
CN113355357B (zh) 2012-12-12 2024-12-03 布罗德研究所有限公司 对用于序列操纵的改进的系统、方法和酶组合物进行的工程化和优化
US9410943B2 (en) 2013-03-14 2016-08-09 The Board Of Trustees Of The Leland Stanford Junior University Methods, compositions and screens for therapeutics for the treatment of synovial sarcoma
WO2014150751A2 (en) 2013-03-15 2014-09-25 Novartis Ag Biomarkers associated with brm inhibition
US10976320B2 (en) 2013-05-21 2021-04-13 The Board Of Trustees Of The Leland Stanford Junior University Methods for identifying and treating cancer patients
EP3018123B1 (en) 2013-07-03 2023-05-10 Takeda Pharmaceutical Company Limited Amide compound
JPWO2015005473A1 (ja) 2013-07-12 2017-03-02 国立研究開発法人国立がん研究センター がんの治療への応答性を予測する方法
EP3022197B1 (en) 2013-07-15 2017-09-06 Boehringer Ingelheim International GmbH Novel tetra- and pentasubstituted benzimidazolium compounds
WO2015046193A1 (ja) 2013-09-25 2015-04-02 塩野義製薬株式会社 Ｔｒｐｖ４阻害活性を有する芳香族複素環式アミン誘導体
CA2935683A1 (en) 2013-12-30 2015-07-09 Lifesci Pharmaceuticals, Inc. Therapeutic inhibitory compounds
GB201402771D0 (en) 2014-02-17 2014-04-02 Isis Innovation Biomarker & therapeutic target for sarcoma
PT3177640T (pt) 2014-08-08 2020-08-31 Univ Leland Stanford Junior Agentes pd-1 de alta afinidade e métodos de utilização
WO2016054491A1 (en) 2014-10-03 2016-04-07 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
US9636323B2 (en) 2014-10-27 2017-05-02 Baylor College Of Medicine Method of treating cancer that overexpresses TopBP1
CN104530013B (zh) 2014-12-04 2016-06-29 中国农业大学 基于吲哚环的吡唑酰胺类化合物作为农用杀菌剂的用途
US9546296B2 (en) 2014-12-15 2017-01-17 Ppg Industries Ohio, Inc. Coating compositions, coatings and methods for sound and vibration damping and water resistance
US9932340B2 (en) 2014-12-18 2018-04-03 Abbvie Inc. Substituted indoles
WO2016105518A1 (en) 2014-12-23 2016-06-30 Dana-Farber Cancer Institute, Inc. Methods to induce targeted protein degradation through bifunctional molecules
US9694084B2 (en) 2014-12-23 2017-07-04 Dana-Farber Cancer Institute, Inc. Methods to induce targeted protein degradation through bifunctional molecules
WO2016160718A1 (en) * 2015-03-27 2016-10-06 University Of Washington Methods for treatment of retinal disease by photoreceptor gene expression modulation
US20180140722A1 (en) 2015-04-06 2018-05-24 The University Of North Carolina At Chapel Hill Methods and compositions for treatment of heart failure
EP3108883A1 (en) * 2015-06-22 2016-12-28 Fundació Institut de Recerca Biomèdica de Bellvitge Therapeutic uses of non-peptide inhibitors of the calcineurin - nfat signalling pathway
WO2017007612A1 (en) 2015-07-07 2017-01-12 Dana-Farber Cancer Institute, Inc. Methods to induce targeted protein degradation through bifunctional molecules
WO2017024318A1 (en) 2015-08-06 2017-02-09 Dana-Farber Cancer Institute, Inc. Targeted protein degradation to attenuate adoptive t-cell therapy associated adverse inflammatory responses
US9630049B2 (en) 2015-09-21 2017-04-25 Joseph D Hartman Reciprocating rehabilitation device
US20170100396A1 (en) 2015-10-07 2017-04-13 F. Hoffmann-La Roche Ag Pyrrolopyrazine derivatives for use in the treatment, amelioration or prevention of influenza
FI3362065T3 (fi) 2015-10-15 2024-06-19 Servier Lab Ivosidenibiä, sytarabiinia ja daunorubisiinia tai idarubisiinia käsittävä yhdistelmähoito akuutin myelooisen leukemian hoitamiseksi
WO2017087885A1 (en) 2015-11-19 2017-05-26 Dana-Farber Cancer Institute, Inc. Methods of identifying compounds that interfere with erg-driven misguidance of baf complexes in tmprss2-erg driven prostate cancers
WO2017118734A1 (en) 2016-01-08 2017-07-13 The Institute Of Cancer Research: Royal Cancer Hospital Inhibitors of ataxia-telangiectasia mutated and rad3-related protein kinase (atr) for use in methods of treating cancer
MA43640A (fr) 2016-02-26 2018-11-28 Agios Pharmaceuticals Inc Inhibiteurs de idh1 pour le traitement de cancers hématologiques et de tumeurs solides
GB201604638D0 (en) 2016-03-18 2016-05-04 Mission Therapeutics Ltd Novel compounds
CN109641874A (zh) 2016-05-10 2019-04-16 C4医药公司 用于靶蛋白降解的c3-碳连接的戊二酰亚胺降解决定子体
EP3454856B1 (en) 2016-05-10 2024-09-11 C4 Therapeutics, Inc. Heterocyclic degronimers for target protein degradation
ES2990061T3 (es) 2016-05-10 2024-11-28 C4 Therapeutics Inc Degronímeros espirocíclicos para la degradación de proteínas diana
US10207998B2 (en) 2016-09-29 2019-02-19 Duke University Substituted benzimidazole and substituted benzothiazole inhibitors of transforming growth factor-β kinase and methods of use thereof
WO2018064589A1 (en) 2016-09-29 2018-04-05 Dana-Farber Cancer Institute, Inc. Targeted protein degradation using a mutant e3 ubiquitin ligase
AU2018219292B2 (en) 2017-02-08 2024-09-26 Dana-Farber Cancer Institute, Inc. Tunable endogenous protein degradation with heterobifunctional compounds
CN110366418A (zh) 2017-02-28 2019-10-22 埃皮兹姆公司 抑制smarca2用于治疗癌症
US11555031B2 (en) 2017-03-20 2023-01-17 The Broad Institute, Inc. Compounds and methods for regulating insulin secretion
TWI791593B (zh) 2017-08-21 2023-02-11 德商馬克專利公司 做為腺苷受體拮抗劑之苯并咪唑衍生物
US20200206344A1 (en) 2017-08-21 2020-07-02 Dana-Farber Cancer Institute, Inc. Methods for modulating the interaction between ews-fli1 and baf complexes
US11472794B2 (en) 2018-01-15 2022-10-18 UCB Biopharma SRL Fused imidazole derivatives as IL-17 modulators
EP3740482A1 (en) 2018-01-17 2020-11-25 Migal Galilee Research Institute Ltd. New methionine metabolic pathway inhibitors
EP3746135A4 (en) 2018-01-30 2022-03-09 Foghorn Therapeutics Inc. METHODS AND COMPOUNDS FOR TREATMENT OF DISEASE
US11497752B2 (en) 2018-01-30 2022-11-15 Foghorn Therapeutics Inc. Compounds and uses thereof
US11447502B2 (en) 2018-05-25 2022-09-20 Rutgers, The State University Of New Jersey Antibacterial agents: dual-targeted RNA polymerase inhibitors
US20210251988A1 (en) 2018-06-21 2021-08-19 Foghorn Therapeutics Inc. Methods of treating disorders
WO2019246423A1 (en) 2018-06-21 2019-12-26 Foghorn Therapeutics Inc. Methods of treating disorders
PT3837256T (pt) 2018-08-17 2023-05-23 Novartis Ag Compostos e composições de ureia como inibidores de smarca2/brm-atpase
US20210171958A1 (en) 2018-08-23 2021-06-10 Foghorn Therapeutics Inc. Methods of treating cancer
WO2020081588A1 (en) 2018-10-17 2020-04-23 Dana-Farber Cancer Institute, Inc. Swi/snf family chromatin remodeling complexes and uses thereof
WO2020081556A2 (en) 2018-10-17 2020-04-23 Dana-Farber Cancer Institute, Inc. Non-canonical swi/snf complex and uses thereof
JP2022508155A (ja) 2018-11-21 2022-01-19 フォグホーン セラピューティクス インコーポレイテッド がんを治療する方法
SG11202106444WA (en) 2018-12-19 2021-07-29 Leo Pharma As Amino-acid anilides as small molecule modulators of il-17
CN113645971B (zh) 2019-01-29 2024-10-18 福宏治疗公司 化合物及其用途
US12509453B2 (en) 2019-01-29 2025-12-30 Foghorn Therapeutics Inc. BRM/BRG1 inhibitors and uses thereof
US12384776B2 (en) 2019-01-29 2025-08-12 Foghorn Therapeutics Inc. Compounds and uses thereof
WO2020191326A1 (en) 2019-03-20 2020-09-24 Sumitomo Dainippon Pharma Oncology, Inc. Treatment of acute myeloid leukemia (aml) with venetoclax failure
PH12022550578A1 (en) 2019-09-12 2024-02-19 Aurigene Discovery Tech Ltd Method for identifying responders to smarca2/4 degraders
US20220396604A1 (en) 2019-10-25 2022-12-15 Dana-Farber Cancer Institute, Inc. Compositions comprising modified smarcb1 and uses thereof
EA202192101A1 (ru) 2019-11-21 2021-12-09 Фогхорн Терапьютикс Инк. Соединения и их применение
WO2021155264A1 (en) 2020-01-29 2021-08-05 Foghorn Therapeutics Inc. Compounds and uses thereof
EP4096667A4 (en) 2020-01-29 2024-03-06 Foghorn Therapeutics Inc. COMPOUNDS AND USES THEREOF
AU2021213811A1 (en) 2020-01-29 2022-07-28 Foghorn Therapeutics Inc. Compounds and uses thereof
EP4096651A4 (en) 2020-01-29 2024-01-24 Foghorn Therapeutics Inc. COMPOUNDS AND THEIR USES
JP7693688B2 (ja) 2020-01-29 2025-06-17 フォグホーン セラピューティクス インコーポレイテッド 化合物およびその使用
CN115484948A (zh) 2020-01-29 2022-12-16 福宏治疗公司 化合物及其用途
US20250283871A1 (en) 2020-03-13 2025-09-11 Dana-Farber Cancer Institute, Inc. Compositions and methods for modulating the interaction between ss18-ssx fusion oncoprotein and nucleosomes
US12383555B2 (en) 2020-05-20 2025-08-12 Foghorn Therapeutics Inc. Methods of treating cancers
EP4153176A4 (en) 2020-05-20 2024-05-29 Foghorn Therapeutics Inc. METHODS OF TREATING CANCER
US12606553B2 (en) 2021-03-09 2026-04-21 Foghorn Therapeutics Inc. Crystalline forms, compositions containing same, and methods of their use
WO2022192621A1 (en) 2021-03-12 2022-09-15 Celgene Corporation Methods for using a hypomethylating agent to treat diseases and disorders based on gene mutation profiles
CN117337179A (zh) 2021-03-19 2024-01-02 福宏治疗公司 Brg1和brm的酶活性抑制剂的治疗方案
US20240374605A1 (en) 2021-07-29 2024-11-14 Foghorn Therapeutics Inc. Methods of treating cancer
CN119343142A (zh) 2022-04-08 2025-01-21 福宏治疗公司 治疗具有与血细胞分化相关的临床显著体征和症状的受试者的方法
US20250339441A1 (en) 2022-04-08 2025-11-06 Foghorn Therapeutics Inc. Methods of treating cancer
US20250325553A1 (en) 2022-04-08 2025-10-23 Foghorn Therapeutics Inc. Methods of treating cancer
EP4564659A4 (en) 2022-07-29 2025-11-05 Denso Corp POWER CONVERSION DEVICE
CN218451564U (zh) 2022-08-09 2023-02-07 宁波立奇电器有限公司 一种双锅双风道式空气炸锅
WO2024086577A1 (en) 2022-10-17 2024-04-25 Foghorn Therapeutics Inc. Methods of reducing or preventing metastases
WO2024216151A1 (en) 2023-04-13 2024-10-17 Foghorn Therapeutics Inc. Combination therapy for treating hematological cancers
WO2024216136A1 (en) 2023-04-13 2024-10-17 Foghorn Therapeutics Inc. Combination therapy for the treatment of hematological cancers

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3717642A (en) * 1969-07-22 1973-02-20 Warner Lambert Co N quinoline 5 aminooxazoles
CN103038231A (zh) * 2010-03-17 2013-04-10 台维克斯医疗公司 Hec1活性调节剂及其方法
CN105473141A (zh) * 2013-03-15 2016-04-06 实发生物医学公司 治疗和/或预防心血管疾病的抗pcsk9化合物和方法
WO2015120320A1 (en) * 2014-02-06 2015-08-13 Rutgers, The State University Of New Jersey Antibacterial agents: n(alpha)-aroyl-n-aryl-phenylalaninamides
CN107531668A (zh) * 2015-02-25 2018-01-02 基因泰克公司 治疗性哒嗪化合物及其用途

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
LEHMANN: "Reaction of Aminothiazoles with 5-Oxazolones", 《CHEMINFORM》 *

Also Published As

Publication number Publication date
US11497752B2 (en) 2022-11-15
US12383560B2 (en) 2025-08-12
WO2019152437A1 (en) 2019-08-08
US20210038611A1 (en) 2021-02-11
US20230138480A1 (en) 2023-05-04
EP3746124A1 (en) 2020-12-09
JP2021512166A (ja) 2021-05-13
EP3746124A4 (en) 2021-10-27

Similar Documents

Publication Publication Date Title
CN112153984A (zh) 化合物及其用途
US12509453B2 (en) BRM/BRG1 inhibitors and uses thereof
JP7479486B2 (ja) 化合物およびその使用
CN116745288B (zh) 化合物及其用途
JP7600396B2 (ja) 化合物及びその使用
JP7531656B2 (ja) 化合物及びその使用
JP2023512038A (ja) 化合物及びその使用
KR20220133258A (ko) 화합물 및 이의 용도
CN115666575A (zh) 化合物及其用途
IL285177B2 (en) Compounds and their use
EA049084B1 (ru) Соединения и их применение

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination